Prognostic features of signal transducer and activator of transcription 3 in an ER(+) breast cancer model system. (January 2014)

• Record Type: Journal Article
• Authors: Liu, Li-Yu D.; Chang, Li-Yun; Kuo, Wen-Hung; Hwa, Hsiao-Lin; Lin, Yi-Shing; Jeng, Meei-Huey; roth, Don A.; Chang, King-Jen; Hsieh, Fon-Jou
• Is Part Of: Cancer informatics. Volume 13(2014)
• Publication Date: 2014-01
• Subjects: STAT3 transcriptional regulatory network -- prognosis -- TAM resistance -- tumorigenesis -- breast cancer; Bioinformatics -- Periodicals; Biology -- Data processing -- Periodicals; Cancer -- Periodicals; Cancer -- Research -- Periodicals; Computational biology -- Periodicals; 570.285
• DOI: 10.4137/CIN.S12493
• Languages: English
• ISSNs: 1176-9351

Abstract

The aberrantly expressed signal transducer and activator of transcription 3 (STAT3) predicts poor prognosis, primarily in estrogen receptor positive (ER(+)) breast cancers. Activated STAT3 is overexpressed in luminal A subtype cells. The mechanisms contributing to the prognosis and/or subtype relevant features of STAT3 in ER(+) breast cancers are through multiple interacting regulatory pathways, including STAT3-MYC, STAT3-ERα, and STAT3-MYC-ERα interactions, as well as the direct action of activated STAT3. These data predict malignant events, treatment responses and a novel enhancer of tamoxifen resistance. The inferred crosstalk between ERα and STAT3 in regulating their shared target gene-METAP2 is partially validated in the luminal B breast cancer cell line-MCF7. Taken together, we identify a poor prognosis relevant gene set within the STAT3 network and a robust one in a subset of patients. VEGFA, ABL1, LYN, IGF2R and STAT3 are suggested therapeutic targets for further study based upon the degree of differential expression in our model.